Virtual Cell for Biomanufacturing
AI-designed approaches for cell state modulation
About Us
We are building the AI layer for CMC (Chemistry, Manufacturing & Controls), one of pharma’s most important yet underserved challenges. Our platform helps pharma better understand the cells behind biologics manufacturing and provides the means to modulate them with precision, enabling faster process development, smoother validation, and lower-cost biologics production.
Biomanufacturing is fundamentally inefficient
Low cell yield limits production
High costs reduce scalability
Trial-and-error slows innovation
Our Solution
Boosting Yields, Reducing Costs & Accelerating Biologics Production
ChemT’s proprietary AI-driven virtual cell platform, CelMo™, sits at the core of our innovation, serving as the foundation for how we understand, predict, and influence cell behavior. Using CelMo™, we develop AI-designed solutions, such as de novo small molecule generation to modulate cells for improved growth, productivity, and product quality in biologics production. By combining deep cellular insight with AI-guided intervention, we aim to enable more robust, scalable, and efficient manufacturing.
Our Team
Our team includes world-leading experts in molecular biology, medicinal chemistry and artificial intelligence from several institutions including Harvard University, Stanford University, National University of Singapore and Scripps Research Institute. Our team members also bring extensive industry experience from leading pharmaceutical companies such as Wuxi Biologics, Johnson & Johnson and Genzyme, ensuring a seamless integration of scientific excellence with industry innovation.
Dr. Ling Wu
Dr. Wu Ling is a seasoned cancer immunologist with over a decade of experience in therapeutics. He was formerly a principal investigator & group leader at BeiGene and serves as an advisor to the International Society of Pharmaceutical Engineering (ISPE). He holds a PhD from the National University of Singapore and is a recipient of the Outstanding Research Award.
Jie Sun
Sun Jie is an AI specialist with deep experience in health data science and AI-driven drug development. She held data science roles at Dana-Farber and Mass General, with research published in The Lancet and AAAI. Previously, she cofounded Basys.ai, a healthtech startup backed by the Mayo Clinic and Eli Lilly. A 40 Under 40 honoree by the Boston Congress of Public Health, she mentors startups at MIT, NUS, and MassChallenge, and writes on AI and entrepreneurship for Forbes. She holds an MS in Health Data Science from Harvard and a BS in Statistics from NUS.
Prof. Nicholas Gascoigne
Prof. Nicholas is a world-renowned immunologist and Fellow of the Royal Society of Biology. A pioneer in T cell biology, he co-discovered the TCR gene with Mark Davis and has over 30 years of research experience. He has held roles at the National University of Singapore, Scripps Research, completed his postdoctoral training at Stanford and is a professor at Georgia Cancer Center. Former President of the Singapore Immunology Society, his work has been cited over 10,000 times, including publications in Nature and Science.
Advisory Board
Dr. Hancheng Zhang, PhD
Dr Zhang is a seasoned medicinal chemist with 15+ years at Johnson & Johnson leading small-molecule drug design, followed by roles as SVP of Chemistry at ChemPartner (managing 300+ scientists) and founder of Innogate Pharma. He is also the former president of the Sino-America Pharmaceutical Professionals Association.
Prof. Charles Cooney
Prof. Charles Cooney is an Advisor to ChemT Biotechnology and a Professor Emeritus of Chemical Engineering at MIT. A pioneer in bioprocessing and pharmaceutical manufacturing, he has authored more than 250 publications and holds over 25 patents. Prof. Cooney has served on the boards of more than 25 biotechnology and pharmaceutical companies, including Codiak Bioscience, Innovent Biologics, and Levitronix Technologies. His expertise spans scalable biologics production, regulatory strategy, and biomanufacturing innovation.
Kheng Nam Lee
Kheng Nam Lee, Senior Advisor to ChemT, is Deputy Chairman of Vertex Venture Holdings and a Venture Partner at Granite Asia. With decades of deep-tech and venture leadership across government and industry, he serves on multiple technology boards and has guided several companies through successful acquisitions.
Dr. Weichang Zhou
Dr. Weichang Zhou, Advisor to ChemT, is Chief Technology Officer of MediLink Therapeutics and a globally distinguished leader in cell culture engineering and biomanufacturing, with over 30 years of industry experience. He has held senior leadership roles at Merck, PDL BioPharma, Genzyme (Sanofi), and WuXi Biologics. His pioneering research, industrial innovation, and leadership have driven a number of publications, patents, and groundbreaking bioprocessing technologies. He earned his Ph.D. from the University of Hannover and conducted postdoctoral research at DECHEMA, ETH Zurich, and the University of Minnesota. He is a recipient of Asia-Pacific Biopharma Excellence Awards CTO of the Year 2023 award (2024), 2025 ECI Cell Culture Engineering Award, and 2025 ECI Integrated Continuous Biomanufacturing (ICB) Award. In 2026 he was elected to the National Academy of Engineering for engineering and leadership in the field of manufacturing and development of biologics.
News and Insights
ChemT Biotechnology and CARsgen Therapeutics Announce Strategic Partnership to Advance Cell Therapy Innovation
Singapore, Dec 2025 — ChemT Biotechnology and CARsgen Therapeutics have entered into a strategic partnership focused on accelerating next-generation cell therapy development and exploring potential IND-enabling collaboration opportunities.
Know More
ChemT Marks a Milestone Moment on the NASDAQ Times Square Tower
New York, Nov 2025 — ChemT Biotechnology was featured on the NASDAQ Times Square tower in New York, marking the conclusion of its participation in the BioTools Innovator 2025 cohort. The milestone reflects a year of rapid progress in advancing its AI-powered biotechnology platform.
ChemT Becomes the First Singapore Company to Win the Lee Kuan Yew Global Business Plan Competition
Singapore Nov 2025- ChemT Biotechnology has made history as the first Singapore company to win the Grand Prize at the 12th Lee Kuan Yew Global Business Plan Competition (LKYGBPC), organised by the Institute of Innovation and Entrepreneurship at Singapore Management University (SMU).